News Center

Discover all of the trending news of the Ipsen Group


153 results

Statement on IRLAB’s mesdopetam Phase IIb trial results

Ipsen has received the top-line results of the Phase IIb trial1 of mesdopetam2 in people with…

Event

J.P. Morgan Conference 2023: Ipsen shares strategy success

Ipsen leaders will attend the J.P. Morgan Healthcare Conference from January 9-12, 2023, in San…

Living with PBC: The Person Behind the Chart

‘Invisible’ diseases like primary biliary cholangitis (PBC) can be difficult to recognise, diagnose and to…

Rare diseases

A Life in a Day of an FOP person: from Empathy to Understand...

You can never truly understand what it’s like to live with an ultra-rare condition unless…

Ipsen anti-corruption system certification renewed in 2022

In December 2021, Ipsen received ISO 37001 certification for its anti-corruption management systems by Eurocompliance,…

Financial information

A word from CEO David Loew

"Our growth platforms have delivered strong sales performance, reflecting improving commercial execution and the strength…

Business

Ipsen becomes a founding sponsor of the second Biolabs innov...

Ipsen announces that it becomes a founding sponsor of the second Biolabs innovation brain hub…

The Ixcellence Network®: celebrating 10 years of progress in...

By Hamzah Baig, Senior Global Medical Affairs Director for Neuroscience at Ipsen   Continuing medical…

‘A Life in a Day’: the realities of living with FOP

By Abbie Pound, Culture and Engagement Director, Patient Centricity Champion, CSR Champion. UK & Ireland…

Ipsen receives SBTi approval for climate targets

In October 2021, Ipsen pledged ambitious action on climate change. Today, we announce that Ipsen’s…

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition…

ILC 2022: Let’s talk PBC

The International Liver Congress (ILC)1 provides a key opportunity for us to meet and…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023